In collaboration with the UW Carbone Cancer Center, we are developing a new approach to the treatment of cancer that has spread beyond the primary tumor (metastatic cancer). This trial involves 3 ways to stimulate a patient’s own immune system to fight their cancer 1) “Immune checkpoint inhibition” (ICI), 2) “in situ vaccination” (ISV), and 3) low-dose radiopharmaceutical therapy (RPT). ICI involves injections of a monoclonal antibody that targets the “immune checkpoints” (the “brakes”) of the immune system that cancer cells use to escape detection by cancer-killing immune cells. ICI therapy results in a lifting of the brakes and in some patients allows the immune system to recognize and actively kill cancer cells throughout the patient’s body. The ICI therapy used in this study is an IV drug called Gilvetmab that is USDA conditionally approved for use in dogs. ISV involves a combination of standard doses of external beam radiation therapy (EBRT) that targets your dog’s primary cancer along with an injection directly into your dog’s primary cancer of an immune stimulant called PIC. The combination of EBRT and PIC has been shown in mouse tumors to turn the mouse’s own tumor into an anticancer vaccine resulting in cures in significant percentage of mice. RPT involves giving a low dose of a radioactive molecule that is designed to target cancer cells specifically. This low dose does not kill cancer cells specifically, rather it changes the way the cancer cells are recognized by the patient’s immune system. We have shown that low-dose radiation, if delivered to all sites of cancer in a mouse, results in enhanced immune killing of the cancer cell. This trial is seperated into 3 arms (Arm# 1, Arm# 2a, Arm# 2b). We will initially enroll patients to Arm #1. After completion of Arm# 1, patients will be randomized between Arm# 2a and Arm# 2b). Clinical Protocol for Arm #1 Dogs with advanced (metastasized, spread) cancer may be eligible for this study. If your dog does enter the clinical trial, ICI therapy will start on Day 1. When your dog is to receive RPT, your dog would first receive an intravenous injection of a radioactive tracer, 86Y-NM600, which is an imaging agent (it is not therapeutic). PET/CT scans will be performed at 1-, 24-, and 48-hours post 86Y-NM600 injection. Your dog will be under general anesthesia for the PET/CT scans. Results of the PET/CT scans will allow us to determine the dose of RPT that will deliver the planned amount of radiation to all tumor sites. Because this is a radioactive substance, your dog would need to be hospitalized until it is determined that your dog is no longer radioactive (up to 6 days). Clinical Protocol for Arm #2a and Arm# 2b Dogs with advanced (metastasized, spread) cancer may be eligible for this study. If your dog does enter the clinical trial, ICI therapy will be started 2 weeks before receiving EBRT and intratumoral PIC. Only half of the dogs in this trial will receive RPT but all dogs will receive ICI, EBRT and intratumoral PIC- your dog will be randomized to either receive RPT or not in addition to the other treatments. If your dog is to receive RPT, your dog would first receive an intravenous injection of a radioactive tracer, 86Y-NM600, which is an imaging agent (it is not therapeutic). PET/CT scans will be performed at 1, 24, and 48 hours post 86Y-NM600 injection. Your dog will be under general anesthesia for the PET/CT scans. Results of the PET/CT scans will allow us to determine the dose of RPT that will deliver the planned amount of radiation to all tumor sites. Because this is a radioactive substance, your dog would need to be hospitalized until it is determined that your dog is no longer radioactive (up to 6 days).

UW Veterinary Cancer Center is enrolling dogs with hemangiosarcoma (HSA) in a combination standard of care chemotherapy plus vaccine immunotherapy. This trial seeks to stimulate the patient's immune system to detect ("Scout out") and kill cancer cells.After spleen removal, ALL dogs will receive the current Standard-of-Care treatment involving chemotherapy plus:Half of the dogs will be randomized to receive an investigational anti-cancer vaccine designed against 35 potential immune targets specific to HSA cancer in addition to the standard chemotherapy the other half of the dogs will, by random assignment) receive a non-therapeutic control vaccine (placebo) in addition to the standard chemotherapyThis fully funded study pays for:All required examination visitsLab work (CBC, blood chemistry, urinalysis)Diagnostics every 8 weeks (thoracic radiographs and abdominal ultrasound)Standard of care chemotherapy (Doxorubicin) x 5 cyclesall investigational vaccine related costsPatients will receive treatment and follow-up rechecks over a year.The study does not pay for splenectomy, which is required for diagnosis and generally performed at emergency or regular clinics.

The purpose of this study is to evaluate the outcomes for dogs treated palliatively with standard amputation (no chemotherapy). Recent data indicates that at least 35% of dogs do not appear to benefit from standard chemotherapy for this disease. To better understand whether chemotherapy is truly beneficial, this trial aims to document the outcomes prospectively and accurately for dogs whose owners have elected to treat only with surgery (amputation). There will be about 120 dogs taking part in this study across North America. Standard therapy for dogs diagnosed with osteosarcoma has long been amputation of the affected limb followed by chemotherapy to prevent or slow the growth and spread of cancer. With this form of treatment, the median survival time of dogs diagnosed with osteosarcoma is between 10-14 months (43% alive at 1-year, 24% alive at 2-years). Importantly, recent large trials have found that 35% of dogs will develop metastatic disease within 15-weeks of surgery, despite chemotherapy. Prior studies from the 1970s and 1980s indicated that the median survival of dogs treated with palliative amputation alone (no chemotherapy) was 4-6 months (12% alive at 1-year, 2% alive at 2-years). However, dogs in the palliative study did not receive all the same screening tests or follow up as dogs receiving chemotherapy in more recent trials. The purpose of this study is to determine outcomes more accurately for dogs undergoing amputation alone for osteosarcoma that have undergone complete screening and follow up imaging.